HuGE Literature Finder
Records
1
-
17
| Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. Scientific reports 2021 Aug 11 (1): 17081. Fekete Ferenc, Mangó Katalin, Déri Máté, Incze Evelyn, Minus Annamária, Monostory Katal |
| Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. The pharmacogenomics journal 2018 Oct . Canet Luz M, Sánchez-Maldonado Jose M, Cáliz Rafael, Ramos Ana Rodríguez, Lupiañez Carmen B, Canhão Helena, Martínez-Bueno Manuel, Escudero Alejandro, Segura-Catena Juana, Sorensen Signe B, Hetland Merete L, Soto-Pino María José, Ferrer Miguel A, García Antonio, Glintborg Bente, Filipescu Ileana, Pérez-Pampin Eva, González-Utrilla Alfonso, Nevot Miguel Ángel López, Conesa-Zamora Pablo, Broeder Alfons den, De Vita Salvatore, Jacobsen Sven Erik Hobe, Collantes-Estevez Eduardo, Quartuccio Luca, Canzian Federico, Fonseca João E, Coenen Marieke J H, Andersen Vibeke, Sainz Ju |
| Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups. Endocrine, metabolic & immune disorders drug targets 2018 Aug . Rabiee Mina, Marjani Abdoljalal, Khajeniazi Safoura, Mojerloo Mohamm |
| Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmacogenomics and personalized medicine 2017 10 93-99. Sychev Dmitrij Alekseevitch, Shuev Grigorij Nikolaevich, Suleymanov Salavat Shejhovich, Ryzhikova Kristina Anatol'evna, Mirzaev Karin Badavievich, Grishina Elena Anatol'evna, Snalina Natalia Evgenievna, Sozaeva Zhannet Alimovna, Grabuzdov Anton Mikhailovich, Matsneva Irina Andreev |
| How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arhiv za higijenu rada i toksikologiju 2016 Mar 67 (1): 1-8. Krasniqi Valon, Dimovski Aleksandar, Domjanovi? Iva Klarica, Bili? Ivan, Božina Na |
| Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s. Drug metabolism and disposition: the biological fate of chemicals 2013 May . Chaudhry AS, Thirumaran RK, Yasuda K, Yang X, Fan Y, Strom SC, Schuetz EG |
| The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2013 Feb 10 (1): 1. Ucar M, Alagozlu H, Sahin S, Ozdemir O |
| A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism. Clinical biochemistry 2013 Jan 46 (1-2): 167-9. López-Parra A M, Borobia A M, Baeza C, Arroyo-Pardo E, Carcas A |
| Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 2012 Dec 13 (1): 1. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL |
| CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications. Bulletin of experimental biology and medicine 2012 Oct 153 (6): 6. Sychev DV, Ignatyev IV, Emelyanov NV, Milovanova VV, Kossovskaya AV, Kukes IV, Tashenova AI, Kukes VG |
| [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2011 Dec 28 (6): 661-5. Huang Sheng-wen, Xiang Dao-kang, Wu Hai-li, Chen Bao-lin, An Bang-quan, Li Gui-fa |
| [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. Terapevticheski? arkhiv 2010 82 (5): 33-9. Kondrat'eva L V, Patrusheva N L, Patrushev L I, Aleksandrova E N, Kovalenko T F, Ostriakova E V, Reshetniak T |
| Prevalence of CYP450 gene variations in patients with type 2 diabetes. Clinical laboratory 2010 56 (7-8): 311-8. Weise A, Prause S, Eidens M, Weber M M, Kann P H, Forst T, Pfützner |
| Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and genomics 2009 Mar 19 (3): 226-34. Huang Sheng-Wen, Chen Hai-Sheng, Wang Xian-Qun, Huang Ling, Xu Ding-Li, Hu Xiao-Jia, Huang Zhi-Hui, He Yong, Chen Kai-Ming, Xiang Dao-Kang, Zou Xiao-Ming, Li Qiang, Ma Li-Qin, Wang Hao-Fei, Chen Bao-Lin, Li Liang, Jia Yan-Kai, Xu Xiang-M |
| Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007 Nov 116 (22): 2563-70. Anderson Jeffrey L, Horne Benjamin D, Stevens Scott M, Grove Amanda S, Barton Stephanie, Nicholas Zachery P, Kahn Samera F S, May Heidi T, Samuelson Kent M, Muhlestein Joseph B, Carlquist John F, |
| In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and genomics 2005 Jul 15 (7): 475-81. Tai Guoying, Farin Frederico, Rieder Mark J, Dreisbach Albert W, Veenstra David L, Verlinde Christophe L M J, Rettie Allan |
| Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004 Jun 24 (6): 720-6. Aquilante Christina L, Lobmeyer Maximilian T, Langaee Taimour Y, Johnson Julie |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: